Exploring the role of respiratory microbiome in lung cancer: A systematic review. (August 2021)

• Record Type: Journal Article
• Authors: Perrone, Fabiana; Belluomini, Lorenzo; Mazzotta, Marco; Bianconi, Maristella; Di Noia, Vincenzo; Meacci, Fiammetta; Montrone, Michele; Pignataro, Daniele; Prelaj, Arsela; Rinaldi, Silvia; Russano, Marco; Sartori, Giulia; Bironzo, Paolo; Facchinetti, Francesco; Menis, Jessica; Tiseo, Marcello; Galetta, Domenico; Novello, Silvia; Pilotto, Sara
• Is Part Of: Critical reviews in oncology/hematology. Volume 164(2021)
• Publication Date: 2021-08
• Subjects: Lung microbiota -- Lung cancer -- Prognosis; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2021.103404
• Languages: English
• ISSNs: 1040-8428

Abstract

Graphical abstract: Highlights: Respiratory microbiome is a promising and unexplored topic for cancer research. Lung cancer is enriched in peculiar microbial communities. Differences in microbiome composition/diversity are reported in lung cancer patients. Lung microbiome detection and modulation in lung cancer deserves dedicated studies. Abstract: Giving the potential contribute in cancer initiation and progression, lung microbiota represents a promising topic in cancer research, although still unexplored. We performed a systematic literature search to identify clinical studies evaluating lung microbiota composition, its correlation with lung cancer patients' clinico-pathological features and prognosis. Of the identified 370 studies, 21 were eligible and included. Although studies were heterogeneous, lung cancer resulted to be enriched in peculiar microbial communities, with differences in composition and diversity according to clinico-pathological parameters. Few studies explored how lung microbiota influences cancer outcome. In light of these findings and borrowing the suggestions coming from gut microbiota, we speculate that respiratory microbiome may influence pathogenesis, progression and outcome of lung cancer. Taking advantage of the experience of chronical lung diseases, prospective studies should be designed to evaluate lung microbiota changes throughout any phase of lung cancer course, particularly with the advent of immunotherapy as pivotal treatment.